Physician profile
Gregory Thomas Smith
NPI 1083608947
$2,341.15
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $384 · 2021: $350 · 2022: $556 · 2023: $378 · 2024: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $341.88 | 2020-2024 | Repatha |
| Cvrx, INC. | $341.17 | 2022-2024 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.04 | 2020-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $240.26 | 2019-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $234.20 | 2019-2022 | |
| Amarin Pharma, INC. | $223.45 | 2019-2023 | |
| Pfizer INC. | $174.90 | 2019-2024 | |
| Esperion Therapeutics, INC. | $148.66 | 2020-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $88.08 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $67.79 | 2019 | |
| Sanofi-Aventis U.S. LLC | $58.27 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $50.52 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $32.15 | 2023 | Arcalyst |
| Novo Nordisk INC | $22.97 | 2023 | Ozempic, Rybelsus |
| Aegerion Pharmaceuticals, INC. | $21.65 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $19.16 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.